Veradermics Hair-Loss Pill Posts Positive Results in 500-Man Trial
NEW YORK, May 28 —
Veradermics' oral hair-loss pill returned positive results in a trial of more than 500 men, putting an FDA submission firmly on the table.
- 500+ men enrolled; results described as positive, the clearest clinical proof point Veradermics has delivered to date
- Stock at $100.13, -33.4x fwd P/E: the market is pricing in ongoing losses, and the valuation rests entirely on pipeline optionality, not earnings
- Watch: FDA submission timeline or next clinical milestone announcement
What Actually Happened
The oral format is the actual story here. Topical treatments have dominated this category for decades and require daily scalp application, a regimen with real compliance drag baked in. A pill collapses that friction. Veradermics is not just adding another product to the same shelf; if the safety profile holds through regulatory review, the company is proposing a different treatment modality, not a better version of an existing one. That distinction matters for market sizing. The 500+ enrollment also gives a future FDA reviewer statistical weight to work with, not a small exploratory cohort that can be set aside as underpowered.
The Catch
"Positive results" is doing heavy lifting in this announcement. Veradermics has not disclosed effect size, safety event rates, or head-to-head performance versus existing standard-of-care treatments. Every clinical-stage biotech with a favorable readout sounds exactly like this at first. The distance between good trial data and an approved drug is where most of these stories end. A -33.4x fwd P/E is a standing reminder that the market already knows the company is burning cash, and the $100.13 price has no earnings floor underneath it.
Bottom Line
This shifts MANE's narrative from speculative to directional, not from speculative to investable. Growth investors get a cleaner FDA story and a format with a genuine compliance argument over daily topical application. Value investors still have nothing to anchor to at a deeply negative forward multiple. The one number to watch: the FDA submission date, which converts today's trial data into a hard regulatory clock with real binary risk attached to it.
Run a full Veradermics analysis, including pipeline valuation and comparable biotech comps, at Basis Report's MANE stock page.
Basis Report does not hold positions in securities discussed. This is not investment advice.